Page last updated: 2024-12-07

s-methyl glutathione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

S-methyl glutathione (SMG) is a naturally occurring derivative of glutathione (GSH), a ubiquitous tripeptide with a wide range of biological functions. SMG is formed by the methylation of GSH at the sulfur atom of the cysteine residue. It has been shown to possess several pharmacological activities, including antioxidant, anti-inflammatory, and neuroprotective effects. Research suggests that SMG may have therapeutic potential in various diseases, such as cancer, Alzheimer’s disease, and Parkinson’s disease. Its precise mechanism of action is still under investigation, but it is thought to exert its effects through multiple pathways, including the modulation of oxidative stress, inflammation, and apoptosis. Studies have shown that SMG can protect cells from oxidative damage, reduce inflammation, and improve cognitive function. Further research is needed to fully elucidate the therapeutic potential of SMG and to develop safe and effective strategies for its clinical application.'

Cross-References

ID SourceID
PubMed CID115260
CHEMBL ID1233129
CHEBI ID141472
SCHEMBL ID1767370
MeSH IDM0068319

Synonyms (38)

Synonym
CHEMBL1233129
GSM ,
l-gamma-glutamyl-s-methylcysteinylglycine
s-methylglutathione ,
2922-56-7
s-methyl gsh
s-methyl-glutathione
glutathione s-methyl ester
glutathione ester
l-gamma-glutamyl-s-methyl-l-cysteinylglycine
DB04701
s-methyl glutathione
G-4000
CHEBI:141472
(2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-methylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
oow3025sr1 ,
glycine, n-(n-l-gamma-glutamyl-s-methyl-l-cysteinyl)-
unii-oow3025sr1
glycine, l-gamma-glutamyl-s-methyl-l-cysteinyl-
glycine, l-.gamma.-glutamyl-s-methyl-l-cysteinyl-
s-methyl-gsh
QTQDDTSVRVWHMO-BQBZGAKWSA-N
SCHEMBL1767370
(2s)-2-amino-5-[[(1r)-2-(carboxymethylamino)-1-(methylsulfanylmethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
DTXSID10183479
sr-01000884011
SR-01000884011-1
bdbm225232
(s)-2-amino-5-((r)-1-(carboxymethylamino)-3-(methylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
n5-((r)-1-((carboxymethyl)amino)-3-(methylthio)-1-oxopropan-2-yl)-l-glutamine
Q27095444
CS-W009893
D95549
HY-W009177
AS-77779
glycine, l-?-glutamyl-s-methyl-l-cysteinyl-
(s)-2-amino-5-(((r)-1-((carboxymethyl)amino)-3-(methylthio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid
AKOS040746355
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
S-substituted glutathioneA glutathione derivative that is glutathione in which the hydrogen of the thiol has been replaced by any other group.
methyl sulfideAny aliphatic sulfide in which at least one of the organyl groups attached to the sulfur is a methyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Glutathione Metabolism1121
Glutathione Synthetase Deficiency1121
5-Oxoprolinuria1121
gamma-Glutamyltransferase Deficiency1121
5-Oxoprolinase Deficiency1121
gamma-Glutamyltranspeptidase Deficiency1121

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lactoylglutathione lyaseHomo sapiens (human)Ki4,168.68990.00122.59479.1400AID74123
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1802734Isothermal Titration Calorimetry (ITC) from Article 10.1186/1471-2091-12-59: \\Delineation of the Pasteurellaceae-specific GbpA-family of glutathione-binding proteins.\\2011BMC biochemistry, Nov-16, Volume: 12Delineation of the Pasteurellaceae-specific GbpA-family of glutathione-binding proteins.
AID221781Compound evaluated for drug latentiation activity by determining relative rate of cleavage by gamma-glutamyl transpeptidase1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Drug latentiation by gamma-glutamyl transpeptidase.
AID74123Inhibition constant of compound against binding of Yeast Glyoxalase I1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (25.00)18.7374
1990's12 (30.00)18.2507
2000's14 (35.00)29.6817
2010's4 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.54 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index23.70 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (18.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]